China Independent Clinical Laboratory Industry Report, 2011-2012
  • Aug./2012
  • Hard Copy
  • USD $1,500
  • Pages:60
  • Single User License
    (PDF Unprintable)       
  • USD $1,400
  • Code: ZYM033
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $2,200
  • Hard Copy + Single User License
  • USD $1,700
The independent clinical laboratory industry starts late and is still in its infancy in China, featuring a limited market size of less than RMB2 billion at present which just accounts for 1%-2% of the total revenue of medical diagnosis. Additionally, the independent clinical laboratories in home market can conduct 1,000 or more diagnostic items, while those in a developed country such as the U.S. are capable of carrying out as many as 4,000 diagnostic items. What is worse, China lags far behind developed countries in diagnostic levels, especially in genetic/molecular diagnostics market segment.

Currently, there are roughly 110 independent clinical laboratories in China, but most of them are small sized. Kingmed Diagnostics, Zhejiang D.A. Diagnostics, ADICON Clinical Laboratories, Inc. and Gaoxin-Da An (invested by DAAN Gene) are the leading companies in Chinese independent clinical laboratory industry and adopt comprehensive diagnostic service mode on the basis of chain operation, together making up approximately 70% market share. Although with a small portion of market share, Beijing NYMPHAVN Biotechnology, Beijing Adinovo Genetic Technology and Zhiyuan Medical Inspection Institute occupy a certain position in the market by virtue of special featured diagnostic service.

The demand from downstream market and the introduction of favorable policies like encouraging the development of private medical institutions arouse keen interest of foreign companies in Chinese independent clinical laboratory market. A large number of foreign enterprises have tapped into Chinese market through technical cooperation or direct capital injection.

In early 2012, DAAN Gene (002030) and Life Technologies co-founded Life Technologies DaAn Diagnostics and announced the official launch of DNA sequencing molecular diagnostics project.

In February 2012, Centre Testing International Corporation cooperated with Amcare Labs International in establishing Johns Hopkins (China) Medical Laboratories in Shanghai (registered capital of USD10 million and equity ratio of 51:49) to carry out the independent medical testing service.

In March 2012, Kindstar Global (Beijing) Medical Technology secured USD20 million in Series C funding from such investors as KPCB China, WI Harper Group, Baird Capital Partners Asia and Mayo Clinic, of which the latter three companies also participated in the company’s Series B financing of USD11 million in June 2011.

The report revolves around the followings:
  • The access policy, industrial policy, international market environment and so forth of Chinese independent clinical laboratory industry;
  • Status quo, competitive landscape, prospects and dynamics of Chinese independent clinical laboratory industry;
  • The effects of the development of upstream diagnostic reagent and instrument, and downstream medical institutions on Chinese independent clinical laboratory industry;
  • Operation, competitive advantages and prospects of 9 independent clinical laboratories including Kingmed Diagnostics, Zhejiang D.A. Diagnostics, ADICON Clinical Laboratories, Inc., DAAN Gene and Kindstar Global (Beijing) Medical Technology, etc.

1 Profile of Independent Clinical Laboratory
1.1 Definition 
1.2 Industry Chain

2 Overview of China Independent Clinical Laboratory Industry
2.1 Policies
2.1.1 Access Policies
2.1.2 Industry Policies
2.2 Global Market
2.2.1 Status Quo
2.2.2 Model Enterprises
2.3 Current Development
2.4 Competitive Landscape
2.5 Dynamics and Prospects

3 Upstream and Downstream Industry of China Independent Clinical Laboratory
3.1 Upstream Sector
3.1.1 Status Quo
3.1.2 Product Mix
3.2 Downstream Sector
3.2.1 Huge Market Scale of Chinese Independent Clinical Laboratory
3.2.2 Medical Reform Encourages Rapid Development of Independent Clinical Laboratory in China
3.2.3 Diversified Demand Promotes the Upgrading of Independent Clinical Laboratory Industry in China

4 Key Players in China
4.1 Kingmed Diagnostics Co., Ltd
4.1.1 Profile
4.1.2 Operation and Prospects
4.2 Zhejiang D.A. Diagnostics Co., Ltd
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 Clients and Suppliers
4.2.6 R & D and Investment
4.2.7 Independent Clinical Laboratory Service
4.3 DAAN Gene Co., Ltd
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.5 Gross Margin
4.3.6 Independent Clinical Laboratory Service
4.4 Beijing NYMPHAVN Biotechnology Corporation Ltd
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 Clients and Suppliers
4.4.6 R & D and Investment
4.5 ADICON Clinical Laboratories, Inc
4.6 Beijing Deyi Biotechnology Medical Co., Ltd
4.7 Beijing Adinovo Genetic Technology Co., Ltd
4.8 Zhiyuan Medical Inspection Institute Co., Ltd
4.9 Kindstar Global (Beijing) Medical Technology Co., Ltd
Industry Chain of Independent Clinical Laboratory
Comparison of Independent Clinical Laboratory between China and the USA by Undertaker 
Policies Concerning Independent Clinical Laboratory Industry in China, 2010-2011
Market Share of Independent Clinical Laboratory Industry in the U.S. by Diagnostic Item, 2003-2010
Market Share of Medical Diagnostics in the USA by Undertaker, 2010
Revenue and Profit of Quest Diagnostics, 2007-2011
Revenue Structure of Quest Diagnostics by Business, 2011
Major M&As of Quest Diagnostics, 2006-2011
Revenue and Profit of Labcorp, 2007-2011
Revenue Breakdown of Labcorp by Business, 2009-2011
Major M&As of Labcorp, 2007-2011
Top 5 Diagnostic Items of Massachusetts General Hospital and Domestic Third-grade Class-A Hospital
Characteristics and Market Share of Major Independent Clinical Laboratories in China, by the End of 2011
Market Size and Growth Rate of In Vitro Diagnostic Industry in China, 2007-2014E
Market Scale and Growth Rate of In Vitro Diagnostic Reagent in China, 2007-2014E
Structure of In Vitro Diagnostic Reagent in China, 2011
Business Revenue and Diagnostics Revenue of Medical Institutions in China, 2010 
Number of Visits in Hospitals and Basic Medical Institutions, 2008-2011
Number of Public and Non-public Hospitals in China, 2008-2011
Layout of D.A. Diagnostics’ Independent Clinical Laboratory
Revenue and Profit of D.A. Diagnostics, 2008-2012
Revenue Breakdown of D.A. Diagnostics by Business, 2008-2011
Revenue Structure of D.A. Diagnostics by Business, 2008-2011
Revenue Breakdown of D.A. Diagnostics by Region, 2008-2011
Revenue Structure of D.A. Diagnostics by Region, 2008-2011
Gross Margin of D.A. Diagnostics by Business, 2008-2011
D.A. Diagnostics’ Revenue from Top 5 Clients and % of Total Revenue, 2008-2011
Name List and Revenue Contribution of D.A. Diagnostics’ Top 5 Clients, 2009-2011
D.A. Diagnostics’ Procurement from Top 5 Suppliers and % of Total Procurement, 2008-2011
Name List and Procurement Contribution of D.A. Diagnostics’ Top 5 Suppliers, 2009-2011
R&D Costs and % of Total Revenue of D.A. Diagnostics, 2008-2011
Revenue and Gross Margin of D.A. Diagnostics’ Independent Diagnostics Business, 2008-2011
Revenue and Gross Margin of D.A. Diagnostics’ Independent Diagnostics Business by Product, 2008-2011
Revenue Structure of D.A. Diagnostics’ Independent Diagnostics Business by Client, 2010-2011
Forecast of D.A. Diagnostics’ Revenue by Business, 2011-2014E
Revenue and Profit of DAAN Gene, 2008-2012
Revenue Breakdown of DAAN Gene by Product, 2008-2011
Revenue Structure of DAAN Gene by Region, 2008-2011
Gross Margin of DAAN Gene by Product, 2008-2011
Revenue and Gross Margin Of DAAN Gene’s Independent Diagnostics Business, 2008-2011
Net Assets, Revenue and Net Income of DAAN Gene’s Subsidiaries Engaging in Independent Diagnostics Business, 2011
Revenue and Profit of NYMPHAVN Biotechnology, 2009-2011
Revenue Breakdown of NYMPHAVN Biotechnology by Product, 2009-2011
Revenue Structure of NYMPHAVN Biotechnology by Product, 2009-2011
Revenue Breakdown of NYMPHAVN Biotechnology by Region, 2010-2011
Gross Margin of NYMPHAVN Biotechnology by Product, 2009-2011
NYMPHAVN Biotechnology’s Revenue from Top 5 Clients and % of Total Revenue, 2009-2011
Name List and Revenue Contribution of NYMPHAVN Biotechnology’s Top 5 Clients, 2009-2011
NYMPHAVN Biotechnology’s Procurement from Top 5 Suppliers and % of Total Procurement, 2009-2011
Name List and Procurement Contribution of NYMPHAVN Biotechnology’s Top 5 Suppliers, 2009-2011
R&D Costs and % of Total Revenue of NYMPHAVN Biotechnology, 2009-2011
Distribution and Established Date of Adicon’s Independent Clinical Laboratory

China Blood Product Industry Report, 2020-2027

With the adjustment in the catalog of medicines covered by national medical insurance system, the scope and reimbursement ratio of almost all blood products for clinical use grow tremendously, which h...

China Medical Robot Industry Report, 2020-2026

Medical robot is the most promising segment of service robot market. By one estimate, globally 7,200 units of medical robots were sold and valued at $2.58 billion in 2019, compared with 5,100 units (u...

China In Vitro Diagnostic (IVD) Industry Report, 2019-2025

In vitro diagnosis (IVD) as a good way to make a rapid and definite diagnosis of diseases early, plays an increasingly crucial role in clinical medicine and related medical research fields. China’s IV...

China Aged Care Industry Report, 2019-2025

China’s society has aged before it gets rich. By the end of 2018, people aged over 60 had numbered 249.5 million in the country, or 17.9% of the total population, of which those aged over 65 were 167 ...

China Dental Industry Report, 2019-2025

Nowadays, the Chinese people have a growing awareness of oral health and healthy behaviors. 60.1% of residents have knowledge about oral health; 24.1% of 5-year-old children and 31.9% of 12-year-old c...

China Hospital Industry Report,2019-2025

The people’s growing awareness of health care and the acceleration of population aging have brought prosperity to China’s hospital industry. As of February 2019, there had been a total of 33,000 hospi...

China Dental Industry Report, 2017-2021

As living standards continue to improve and the awareness of oral health grows, consumers’ demand for dental services has kept increasing and the dental industry in China has witnessed robust developm...

China Interferon Industry Report, 2016-2021

Interferon is mainly used for the treatment of hepatitis B, hepatitis C, multiple sclerosis, condyloma acuminatum and other diseases. Wherein, IFN-α is mainly suitable for curing hepatitis B and hepat...

China Hospital Industry Report,2016-2020

In recent years, "Opinions on Promoting the Development of Health Service Industry" and other related policies, the people’s growing awareness of health care and the acceleration of population aging h...

China Aged Care Industry Report, 2016-2020

China entered the aging society early in 1999. By the end of 2015, China’s population aged over 60 reached 222 million and the old-age dependency ratio 13.9%. By 2020, China’s population aged over 60 ...

China Medical Robotics Industry Report, 2016-2020

Medical robotics can be used in surgery, rescue, transport, care, rehabilitation, dispensing and so on for the sick and wounded. Especially, surgical, rehabilitation and dispensing robots are the R &a...

China Dental Industry Report, 2016-2020

The dental industry refers to medical industrial chain on the basis of oral medical consumption, consisting mainly of dental apparatus (equipments and consumables), dental medical services, etc. With ...

China Medical Imaging Diagnosis Industry Report, 2015-2019

Against the background of a surge in social demand, handsome profit and the favorable opportunity brought by health care reform, the medical imaging industry, especially medical imaging equipment indu...

China Heparin Industry Report, 2015-2018

As the world's largest heparin API producer and exporter, China seizes about 80% share of the global heparin API market. After the explosive growth in 2008-2010, the stagnant international market and ...

Global and China Stem Cell Industry Report, 2015-2018

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Currently, stem cells are used to treat hund...

China Hospital Industry Report, 2015-2018

Stimulated by the demand, the number of hospitals in China rose from 21,979 in 2011 to 26,479 at the end of May 2015, an increase of 4,500 in total. Among them, public hospitals showed an overall decl...

China Independent Clinical Laboratory Industry Report, 2015-2018

The independent clinical laboratory originated from the U.S. and is relatively mature in developed countries/regions like North America, Europe, and Japan, whose independent clinical laboratory market...

China Medical Robot Industry Report, 2014-2018

Medical robots can be applied to surgeries, rescue, transport, nursing and rehabilitation of the sick and wounded. Wherein, surgery and rehabilitation robots are two striking market segments. Due to ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号